|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7595048B2
(en)
|
2002-07-03 |
2009-09-29 |
Ono Pharmaceutical Co., Ltd. |
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
|
|
AU2003270439B2
(en)
|
2002-09-11 |
2009-09-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
HUE039237T2
(hu)
|
2004-10-06 |
2018-12-28 |
Mayo Found Medical Education & Res |
B7-H1 és PD-1 vesesejt karcinoma kezelésében
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP2399932B1
(en)
|
2005-05-12 |
2016-11-16 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
|
AU2012204032B2
(en)
*
|
2005-06-08 |
2014-01-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
|
|
EP3130350A1
(en)
*
|
2005-06-08 |
2017-02-15 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
|
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
RU2423375C2
(ru)
*
|
2005-07-26 |
2011-07-10 |
СиЭмЭс ПЕПТАЙДЗ ПЭЙТЕНТ ХОЛДИНГ КОМПАНИ ЛИМИТЕД |
Новые биологически активные пептиды и их новое применение
|
|
EP1777523A1
(en)
*
|
2005-10-19 |
2007-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
US8216996B2
(en)
|
2006-03-03 |
2012-07-10 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
DK2035549T3
(da)
|
2006-05-31 |
2014-10-13 |
Childrens Medical Center |
Abcb5-positive mesenkymale stamceller som immunmodulatorer
|
|
AU2007342338A1
(en)
*
|
2006-09-20 |
2008-07-17 |
The Johns Hopkins University |
Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
|
|
ME02269B
(me)
|
2006-10-02 |
2016-04-28 |
Medarex Inc |
Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
|
|
NZ594510A
(en)
*
|
2006-12-27 |
2012-06-29 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
|
HUE027593T2
(en)
|
2007-04-12 |
2016-11-28 |
Brigham & Womens Hospital Inc |
ABCB5 targeting cancer therapy
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
JP2010533649A
(ja)
|
2007-07-13 |
2010-10-28 |
ザ ジョンズ ホプキンス ユニバーシティー |
Ｂ７−ｄｃ改変体
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
|
US8168757B2
(en)
*
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP5770624B2
(ja)
|
2008-04-09 |
2015-08-26 |
ジェネンテック， インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
|
JP5945096B2
(ja)
*
|
2008-07-04 |
2016-07-05 |
小野薬品工業株式会社 |
抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX2011002250A
(es)
*
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
DK3130923T3
(da)
|
2008-11-14 |
2020-05-11 |
Brigham & Womens Hospital Inc |
Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
|
|
SI2370593T1
(sl)
|
2008-11-28 |
2016-08-31 |
Emory University |
Postopek za določanje učinkovitosti antagonista pd-1
|
|
US8217149B2
(en)
*
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
JPWO2010101249A1
(ja)
|
2009-03-06 |
2012-09-10 |
国立大学法人三重大学 |
Ｔ細胞の機能増強方法
|
|
MA33127B1
(fr)
|
2009-03-30 |
2012-03-01 |
Eisai R&D Man Co Ltd |
Composition liposomique
|
|
EP2445932B1
(en)
|
2009-06-26 |
2018-02-28 |
Soricimed Biopharma Inc. |
Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
|
|
CN104826106B
(zh)
|
2009-09-30 |
2019-01-11 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8907053B2
(en)
*
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
|
ES2669310T3
(es)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
CN102250910B
(zh)
*
|
2011-05-31 |
2013-01-30 |
苏州大学 |
一种人可溶性b7-dc定量检测试剂盒
|
|
CN103732238A
(zh)
*
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
CN109517059B
(zh)
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
AU2012322999B2
(en)
|
2011-10-11 |
2017-08-10 |
Universitat Zurich Prorektorat Mnw |
Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
|
|
BR112014009526B8
(pt)
*
|
2011-10-17 |
2023-01-17 |
Herlev Hospital |
Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
|
|
ES2529143B1
(es)
|
2011-10-21 |
2015-10-26 |
Abbvie Inc. |
Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
CH707030B1
(de)
|
2011-10-21 |
2015-03-13 |
Abbvie Inc |
Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
|
|
LT2785375T
(lt)
*
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
|
GB201120779D0
(en)
|
2011-12-02 |
2012-01-11 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
WO2013090552A1
(en)
*
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
BR112014017876B1
(pt)
|
2012-01-20 |
2023-04-11 |
Centre Hospitalier Regional Universitaire De Montpellier |
Constructo direcionador compreendendo interferon alfa 2 humano mutante e composição farmacêutica contendo o mesmo
|
|
WO2013122262A1
(en)
|
2012-02-16 |
2013-08-22 |
Vlp Therapeutics, Llc |
Virus like particle composition
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
|
JP2015512910A
(ja)
*
|
2012-03-29 |
2015-04-30 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物
|
|
PL2836234T3
(pl)
|
2012-04-12 |
2020-02-28 |
Yale University |
Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
HUE064187T2
(hu)
*
|
2012-05-25 |
2024-02-28 |
Cellectis |
Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
|
|
BR112014032276A2
(pt)
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
|
US9890215B2
(en)
*
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN103566377A
(zh)
*
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014121085A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
|
WO2014124217A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Albert Einstein College Of Medicine Of Yeshiva University |
A selective high-affinity immune stimulatory reagent and uses thereof
|
|
EP2954327A1
(en)
|
2013-02-07 |
2015-12-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
|
SG10201710473VA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
MX2015014181A
(es)
|
2013-04-09 |
2016-05-24 |
Boston Biomedical Inc |
2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
|
|
SG11201508528TA
(en)
|
2013-05-02 |
2015-11-27 |
Anaptysbio Inc |
Antibodies directed against programmed death-1 (pd-1)
|
|
CN103242448B
(zh)
*
|
2013-05-27 |
2015-01-14 |
郑州大学 |
一种全人源化抗pd-1单克隆抗体及其制备方法和应用
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
CN111423511B
(zh)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
与pd-1结合的抗原结合蛋白
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
US9637532B2
(en)
|
2013-07-12 |
2017-05-02 |
Vlp Therapeutics, Llc |
Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
|
|
SG11201600310QA
(en)
|
2013-07-16 |
2016-02-26 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
SG11201601679TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
|
SG11201601685TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
Cyclic peptidomimetic compounds as immunomodulators
|
|
ES2675027T3
(es)
|
2013-09-06 |
2018-07-05 |
Aurigene Discovery Technologies Limited |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
PT3702373T
(pt)
|
2013-09-13 |
2022-09-27 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
|
|
KR20160055269A
(ko)
|
2013-09-20 |
2016-05-17 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
US9884026B2
(en)
|
2013-11-01 |
2018-02-06 |
Yale University |
Modular particles for immunotherapy
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
EP4566623A3
(en)
*
|
2013-12-20 |
2025-08-20 |
Intervet International B.V. |
Caninized antibodies
|
|
GB201322725D0
(en)
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
AU2014372309C1
(en)
|
2013-12-24 |
2017-12-14 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
|
CN113637692A
(zh)
|
2014-01-15 |
2021-11-12 |
卡德门企业有限公司 |
免疫调节剂
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
EP3102605B1
(en)
|
2014-02-04 |
2018-11-14 |
Pfizer Inc |
Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
|
|
KR20160108568A
(ko)
|
2014-02-04 |
2016-09-19 |
인사이트 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
CN114081946A
(zh)
|
2014-03-12 |
2022-02-25 |
耶达研究与开发有限公司 |
降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
|
|
CA2936962C
(en)
|
2014-03-14 |
2024-03-05 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
KR20170005492A
(ko)
|
2014-05-28 |
2017-01-13 |
아이데닉스 파마슈티칼스 엘엘씨 |
암의 치료를 위한 뉴클레오시드 유도체
|
|
MX389695B
(es)
|
2014-06-11 |
2025-03-20 |
Kathy A Green |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
|
US10301624B2
(en)
|
2014-06-25 |
2019-05-28 |
The General Hospital Corporation |
Targeting human satellite II (HSATII)
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
|
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
WO2016006241A1
(ja)
|
2014-07-09 |
2016-01-14 |
日本全薬工業株式会社 |
抗イヌｐｄ－１抗体又は抗イヌｐｄ－ｌ１抗体
|
|
ES2909957T3
(es)
|
2014-07-16 |
2022-05-11 |
Transgene |
Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios
|
|
AU2015289081B2
(en)
|
2014-07-16 |
2020-02-06 |
Transgene Sa |
Combination of oncolytic virus with immune checkpoint modulators
|
|
CN106999561A
(zh)
|
2014-07-18 |
2017-08-01 |
阿德瓦希斯股份有限公司 |
用于治疗前列腺癌的pd‑1拮抗剂和基于李斯特菌的疫苗的组合
|
|
EP3171892B1
(en)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1 antibodies
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
WO2016015095A1
(en)
*
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
PL3177644T3
(pl)
|
2014-08-05 |
2021-06-14 |
MabQuest SA |
Immunologiczne reagenty wiążące do PD-1
|
|
RU2722212C9
(ru)
|
2014-08-05 |
2020-07-23 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Анти-pd-l1 антитела
|
|
CA2957387A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Hyogo College Of Medicine |
Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
|
|
JP6824154B2
(ja)
|
2014-08-08 |
2021-02-03 |
ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ |
修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
|
|
US10385101B2
(en)
|
2014-08-08 |
2019-08-20 |
Vlp Therapeutics, Llc |
Virus like particle comprising modified envelope protein E3
|
|
KR20170042778A
(ko)
*
|
2014-08-19 |
2017-04-19 |
고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 |
면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
|
|
EP3185866A1
(en)
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
SG11201701669PA
(en)
|
2014-09-11 |
2017-04-27 |
Vlp Therapeutics Llc |
Flavivirus virus like particle
|
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EP3201230B1
(en)
|
2014-09-30 |
2020-12-23 |
Intervet International B.V. |
Pd-l1 antibodies binding canine pd-l1
|
|
US10039564B2
(en)
|
2014-09-30 |
2018-08-07 |
Ethicon Llc |
Surgical devices having power-assisted jaw closure and methods for compressing and sensing tissue
|
|
IL251669B2
(en)
|
2014-10-10 |
2023-02-01 |
Idera Pharmaceuticals Inc |
Cancer treatment using a tlr9 agonist with checkpoint inhibitors
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3215182B1
(en)
|
2014-11-05 |
2023-01-04 |
The Regents of The University of California |
Combination immunotherapy
|
|
US20170326234A1
(en)
*
|
2014-12-02 |
2017-11-16 |
Celgene Corporation |
Combination therapies
|
|
WO2016089830A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
US10442819B2
(en)
|
2014-12-05 |
2019-10-15 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
|
EP3226690B1
(en)
|
2014-12-05 |
2020-05-20 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
|
AU2015360667B2
(en)
*
|
2014-12-09 |
2021-09-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cluster of differentiation 274 gene
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
JP6767096B2
(ja)
*
|
2014-12-11 |
2020-10-14 |
リティックス バイオファーマ エイエス |
免疫チェックポイント阻害剤の組み合わせ
|
|
US10849862B2
(en)
|
2014-12-26 |
2020-12-01 |
Theravalues Corporation |
Formulation of curcumin and anti-PD-1 antibody
|
|
EP3240801B1
(en)
|
2014-12-31 |
2021-01-20 |
Checkmate Pharmaceuticals, Inc. |
Combination tumor immunotherapy
|
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
GB201500374D0
(en)
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
US20180017568A1
(en)
*
|
2015-01-29 |
2018-01-18 |
Konica Minolta, Inc. |
Method for simultaneously analyzing blood cells having interactive molecules
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
AU2016219161A1
(en)
*
|
2015-02-12 |
2017-08-31 |
The Johns Hopkins University |
Inhibition of Yap for breaking tumor immune tolerance
|
|
CN107949397A
(zh)
|
2015-02-13 |
2018-04-20 |
特兰斯吉恩股份有限公司 |
免疫治疗疫苗和抗体组合治疗
|
|
SG10201810615VA
(en)
|
2015-02-26 |
2019-01-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
EP3265122B1
(en)
|
2015-03-04 |
2022-05-04 |
Merck Sharp & Dohme Corp. |
Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
|
|
CA2978226C
(en)
|
2015-03-04 |
2025-02-18 |
Eisai R&D Management Co., Ltd. |
COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
|
|
CA3220902A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
JP6826055B2
(ja)
|
2015-03-13 |
2021-02-03 |
サイトメックス セラピューティクス インコーポレイテッド |
抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
AU2016235362B2
(en)
|
2015-03-23 |
2021-12-16 |
Jounce Therapeutics, Inc. |
Antibodies to ICOS
|
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
ES2813580T3
(es)
|
2015-04-17 |
2021-03-24 |
Bristol Myers Squibb Co |
Composiciones que comprenden una combinación de ipilimumab y nivolumab
|
|
KR20170138555A
(ko)
|
2015-04-28 |
2017-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
|
|
RU2752729C2
(ru)
|
2015-05-18 |
2021-07-30 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Пролекарства альвоцидиба, имеющие повышенную биодоступность
|
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
RU2017145940A
(ru)
*
|
2015-05-29 |
2019-07-02 |
Дайнэвокс Текнолоджиз Корпорейшн |
Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
|
|
KR20180014009A
(ko)
|
2015-05-29 |
2018-02-07 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
|
|
US20180140572A1
(en)
|
2015-06-03 |
2018-05-24 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
KR102661066B1
(ko)
|
2015-06-12 |
2024-04-25 |
매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 |
면역반응의 조절을 위한 방법 및 항체
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
US10869924B2
(en)
|
2015-06-16 |
2020-12-22 |
Merck Patent Gmbh |
PD-L1 antagonist combination treatments
|
|
CN107801379B
(zh)
*
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
|
PL3319635T3
(pl)
*
|
2015-06-24 |
2021-10-25 |
Immodulon Therapeutics Limited |
Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
|
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
US10513558B2
(en)
|
2015-07-13 |
2019-12-24 |
Cytomx Therapeutics, Inc. |
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
|
|
DK3322731T3
(da)
|
2015-07-14 |
2021-03-08 |
Bristol Myers Squibb Co |
Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1)
|
|
CN111375066B
(zh)
|
2015-07-16 |
2023-04-25 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
SI3328419T1
(sl)
|
2015-07-30 |
2021-11-30 |
Macrogenics, Inc. |
PD-1-vezavne molekule in postopki uporabe le-teh
|
|
WO2017023753A1
(en)
|
2015-07-31 |
2017-02-09 |
University Of Florida Research Foundation, Inc. |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
|
KR20180036996A
(ko)
|
2015-08-04 |
2018-04-10 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 치료 및 그의 용도 및 방법
|
|
EP3331918A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
CA2994631A1
(en)
|
2015-08-07 |
2017-02-16 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
HRP20241381T1
(hr)
|
2015-08-11 |
2024-12-20 |
WuXi Biologics Ireland Limited |
Nova anti-pd-1 protutijela
|
|
GEP20207182B
(en)
|
2015-08-13 |
2020-11-25 |
Merck Sharp & Dohme |
Cyclic di-nucleotide compounds as sting agonists
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
KR20220131277A
(ko)
|
2015-09-01 |
2022-09-27 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
|
MY197664A
(en)
|
2015-09-03 |
2023-06-30 |
Ono Pharmaceutical Co |
Immunity enhancing agent for cancer by allergin-1 antagonist
|
|
WO2017049143A1
(en)
*
|
2015-09-18 |
2017-03-23 |
Dana-Farber Cancer Institute, Inc. |
Methods of reducing liver pd-1-expressing cd8+t cells using pd-1 fc fusion proteins that bind fc receptors
|
|
EP3352858A4
(en)
*
|
2015-09-21 |
2019-04-17 |
Merck Sharp & Dohme Corp. |
ANTIBODIES BINDING TO HUMAN PROGRAMMED DEATH LIGANDS 2 (PD-L2) AND USE THEREOF
|
|
US11219694B2
(en)
*
|
2015-09-24 |
2022-01-11 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for reducing metastases
|
|
KR20230125094A
(ko)
|
2015-09-25 |
2023-08-28 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
US10981991B2
(en)
*
|
2015-09-29 |
2021-04-20 |
Shanghai Zhangjiang Biotechnology Co., Ltd. |
PD-1 antibodies and uses thereof
|
|
EP3355920A4
(en)
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
|
|
US10947598B2
(en)
|
2015-09-29 |
2021-03-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for determining the metabolic status of lymphomas
|
|
MA43018B1
(fr)
|
2015-10-02 |
2021-11-30 |
Hoffmann La Roche |
Anticorps anti-pd1 et procédés d'utilisation
|
|
RS62258B1
(sr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Bispecifična antitela specifična za pd1 i tim3
|
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
|
AU2016344459B2
(en)
|
2015-10-28 |
2023-10-05 |
Yale University |
Humanized anti-DKK2 antibody and uses thereof
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
WO2017080920A1
(en)
*
|
2015-11-12 |
2017-05-18 |
Hookipa Biotech Ag |
Arenavirus particles as cancer vaccines
|
|
TWI821748B
(zh)
|
2015-11-18 |
2023-11-11 |
美商必治妥施貴寶公司 |
使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
|
|
CA3006934A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods of use thereof
|
|
MX363780B
(es)
|
2015-12-03 |
2019-04-03 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
EP4541807A3
(en)
|
2015-12-18 |
2025-09-24 |
Intervet International B.V. |
Caninized human antibodies to human and canine il-4r alpha
|
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
|
BR112018012801B1
(pt)
|
2015-12-22 |
2024-03-12 |
Regeneron Pharmaceuticals, Inc |
Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
|
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
AU2017205531B2
(en)
|
2016-01-08 |
2021-05-13 |
Les Laboratoires Servier |
Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator
|
|
CA3010678A1
(en)
|
2016-01-10 |
2017-07-20 |
Neotx Therapeutics Ltd. |
Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
WO2017125815A2
(en)
|
2016-01-22 |
2017-07-27 |
MabQuest SA |
Immunological reagents
|
|
EP3998281A1
(en)
|
2016-02-05 |
2022-05-18 |
Orionis Biosciences BV |
Cd8 binding agents
|
|
US11661455B2
(en)
|
2016-02-05 |
2023-05-30 |
Orionis Biosciences BV |
Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
|
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
|
|
EP3213768A1
(en)
|
2016-03-01 |
2017-09-06 |
LODOCO CLINICAL Kft |
Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
KR102793563B1
(ko)
|
2016-03-04 |
2025-04-11 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양 치료용 제제 및 조성물
|
|
CN109069573B
(zh)
|
2016-03-07 |
2022-04-05 |
弗拉芒区生物技术研究所 |
结合cd20的单结构域抗体
|
|
US20170252417A1
(en)
|
2016-03-07 |
2017-09-07 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
HUE053172T2
(hu)
|
2016-03-14 |
2021-06-28 |
Hoffmann La Roche |
Oligonukleotidok a PD-L1 expresszió csökkentésére
|
|
US10947317B2
(en)
|
2016-03-15 |
2021-03-16 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
KR102646979B1
(ko)
*
|
2016-03-30 |
2024-03-13 |
마이크로바이오 컴퍼니 엘티디. |
면역 체크포인트 조절제 및 공생 미생물군에 의한 발효 산물로의 병용 암 치료법
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
JOP20170083B1
(ar)
|
2016-04-07 |
2022-03-14 |
Glaxosmithkline Ip Dev Ltd |
أميدات هتيروسيكلية مفيدة كمعدلات بروتين
|
|
BR112018071153A2
(pt)
|
2016-04-15 |
2019-04-16 |
Immunext, Inc. |
anticorpos anti-vista humano e uso dos mesmos
|
|
EP3448392A4
(en)
|
2016-04-28 |
2020-01-15 |
Emory University |
ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
|
|
US12029724B2
(en)
|
2016-04-28 |
2024-07-09 |
Eisai R&D Management Co., Ltd. |
Method for inhibiting tumor growth
|
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
CA3023881A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン－ベータおよびその使用
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
WO2017201043A1
(en)
*
|
2016-05-16 |
2017-11-23 |
Concert Pharmaceuticals, Inc. |
Combination therapy for treating cancer
|
|
WO2017201432A2
(en)
|
2016-05-19 |
2017-11-23 |
Jounaidi Youssef |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
SG11201810704WA
(en)
|
2016-05-31 |
2018-12-28 |
Taiho Pharmaceutical Co Ltd |
Sulfonamide compound or salt thereof
|
|
PT3464368T
(pt)
*
|
2016-06-02 |
2023-08-17 |
Bristol Myers Squibb Co |
Utilização de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 no tratamento de linfoma
|
|
HRP20230864T1
(hr)
|
2016-06-02 |
2023-11-10 |
Bristol-Myers Squibb Company |
Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
|
|
KR20240134249A
(ko)
|
2016-06-03 |
2024-09-06 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
|
JP2019517498A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
|
|
US20190298705A1
(en)
|
2016-06-08 |
2019-10-03 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
|
CA3026983A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
JP7185530B2
(ja)
|
2016-06-13 |
2022-12-07 |
トルク セラピューティクス， インコーポレイテッド |
免疫細胞機能を促進するための方法および組成物
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
US20200339659A1
(en)
|
2016-06-21 |
2020-10-29 |
Io Biotech Aps |
Pdl1 peptides for use in cancer vaccines
|
|
DK3476865T5
(da)
|
2016-06-28 |
2024-09-09 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
AU2017300123A1
(en)
|
2016-07-20 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as PERK inhibitors
|
|
JP2019528311A
(ja)
|
2016-08-03 |
2019-10-10 |
ネクストキュア インコーポレイテッド |
Ｌａｉｒシグナル伝達を調節するための組成物及び方法
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
KR20230044038A
(ko)
|
2016-08-09 |
2023-03-31 |
키맵 리미티드 |
항-icos 항체
|
|
CN118252927A
(zh)
|
2016-08-19 |
2024-06-28 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
EP3500294A4
(en)
*
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
US10372100B2
(en)
*
|
2016-08-29 |
2019-08-06 |
Ge Healthcare Bio-Sciences Corp. |
Manufacturing system for biopharmaceutical products
|
|
EP3858365B1
(en)
|
2016-09-01 |
2024-01-31 |
Chimera Bioengineering Inc. |
Gold optimized car t-cells
|
|
RS61204B1
(sr)
|
2016-09-14 |
2021-01-29 |
Abbvie Biotherapeutics Inc |
Anti-pd-1 antitela
|
|
JP2019533645A
(ja)
|
2016-09-16 |
2019-11-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
KR102644544B1
(ko)
|
2016-09-21 |
2024-03-11 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
|
WO2018064013A1
(en)
|
2016-09-27 |
2018-04-05 |
Peregrine Pharmaceuticals, Inc. |
METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
|
|
TN2020000158A1
(en)
|
2016-10-04 |
2022-04-04 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
CA3039774A1
(en)
|
2016-10-10 |
2018-04-19 |
The National Institute for Biotechnology in the Negev Ltd. |
Non-cytotoxic modified cells and use thereof
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
CN110072552A
(zh)
|
2016-10-14 |
2019-07-30 |
默沙东公司 |
用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合
|
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
|
JP7420335B2
(ja)
|
2016-10-26 |
2024-01-23 |
デンカ株式会社 |
変異型ヒトＤＮＡポリメラーゼε
|
|
MA49863A
(fr)
|
2016-11-01 |
2020-06-17 |
Anaptysbio Inc |
Anticorps dirigés contre la mort programmée 1 (pd -1)
|
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
|
CN110392694B
(zh)
|
2016-11-02 |
2023-08-04 |
震动疗法股份有限公司 |
针对pd-1的抗体及其用途
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US11471515B2
(en)
|
2016-11-09 |
2022-10-18 |
The Brigham And Women's Hospital, Inc. |
Restoration of tumor suppression using MRNA-based delivery system
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
US11230596B2
(en)
|
2016-11-30 |
2022-01-25 |
Mereo Biopharma 5, Inc. |
Methods for treatment of cancer comprising TIGIT-binding agents
|
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
JP2020500878A
(ja)
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
MA50949B1
(fr)
|
2016-12-07 |
2023-12-29 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
EP3564678A4
(en)
|
2016-12-28 |
2020-08-12 |
Kinki University |
PROCESS FOR SELECTING INDIVIDUALS TO WHOM AN IMMUNE CHECKPOINT INHIBITOR SHOULD BE ADMINISTERED
|
|
PL3565844T3
(pl)
|
2017-01-09 |
2023-06-12 |
Tesaro Inc. |
Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
IL268346B2
(en)
|
2017-02-06 |
2024-08-01 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
EP3576765B1
(en)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
EP3580230A1
(en)
|
2017-02-07 |
2019-12-18 |
VIB vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
WO2018147275A1
(ja)
|
2017-02-08 |
2018-08-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
WO2018150326A1
(en)
|
2017-02-15 |
2018-08-23 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
キナーゼ阻害剤としての複素環式アミド
|
|
WO2018160540A1
(en)
|
2017-02-28 |
2018-09-07 |
Sanofi |
Therapeutic rna
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
IL322509A
(en)
|
2017-03-09 |
2025-10-01 |
Genmab As |
Antibodies against PD-L1
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
|
EP3604345B1
(en)
|
2017-03-31 |
2023-05-10 |
Toagosei Co., Ltd. |
Antitumor peptide having pd-1 signal sequence and utilization thereof
|
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
|
JP7426825B2
(ja)
|
2017-04-03 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
|
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
JP7718815B2
(ja)
|
2017-04-21 |
2025-08-05 |
シルラゼン， インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
US11845798B2
(en)
|
2017-05-02 |
2023-12-19 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
KR20200018436A
(ko)
|
2017-05-09 |
2020-02-19 |
테사로, 인코포레이티드 |
암 치료를 위한 조합 요법
|
|
WO2018208667A1
(en)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
CA3063715A1
(en)
|
2017-05-18 |
2018-11-22 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
MA50467A
(fr)
|
2017-05-26 |
2020-09-02 |
Taiho Pharmaceutical Co Ltd |
Potentialisateur d'effet antitumoral utilisant un nouveau composé biphényle
|
|
CA3065077C
(en)
|
2017-05-26 |
2022-09-20 |
Taiho Pharmaceutical Co., Ltd. |
Novel biphenyl compound or salt thereof
|
|
US11723975B2
(en)
|
2017-05-30 |
2023-08-15 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
|
|
IL322104A
(en)
|
2017-05-30 |
2025-09-01 |
Bristol Myers Squibb Co |
Treatment of lag-3 positive tumors
|
|
US12435128B2
(en)
|
2017-05-31 |
2025-10-07 |
Taiho Pharmaceutical Co., Ltd. |
Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
US11559504B2
(en)
|
2017-06-02 |
2023-01-24 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
WO2018226336A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
|
|
WO2018225033A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
EP3624841A4
(en)
*
|
2017-06-15 |
2021-01-27 |
Cancer Advances, Inc., |
COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110769827A
(zh)
|
2017-06-23 |
2020-02-07 |
博笛生物科技有限公司 |
药物组合物
|
|
JP2020525411A
(ja)
|
2017-06-26 |
2020-08-27 |
ベイジーン リミテッド |
肝細胞癌のための免疫療法
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
EP3646869B1
(en)
|
2017-06-30 |
2025-08-06 |
Taiho Pharmaceutical Co., Ltd. |
Chemotherapy for cancer using azabicyclo compound
|
|
US20200140383A1
(en)
|
2017-07-03 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物
|
|
AU2018302283B2
(en)
|
2017-07-20 |
2025-07-10 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
CA3071538A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene sting agonists for cancer treatment
|
|
AU2018309339C1
(en)
|
2017-08-04 |
2025-08-21 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
|
JP2020529421A
(ja)
|
2017-08-04 |
2020-10-08 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
|
|
WO2019032663A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
PD-1 AND PD-L1 BINDING AGENTS
|
|
CN111511763B
(zh)
|
2017-08-09 |
2024-05-31 |
奥里尼斯生物科学有限公司 |
Cd8结合剂
|
|
SG11202001063QA
(en)
|
2017-08-09 |
2020-03-30 |
Orionis Biosciences Inc |
Clec9a binding agents and use thereof
|
|
JP7250764B2
(ja)
|
2017-08-18 |
2023-04-03 |
コセラ バイオサイエンス， インコーポレイテッド |
Ｔｇ０２の多形形態
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
EP3679070A1
(en)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
MX2020003770A
(es)
|
2017-09-30 |
2020-07-29 |
Tesaro Inc |
Terapias de combinacion para tratar cancer.
|
|
TW201927771A
(zh)
|
2017-10-05 |
2019-07-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
可作為蛋白質調節劑之雜環醯胺及其使用方法
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
CA3076859A1
(en)
|
2017-10-06 |
2019-04-11 |
Tesaro, Inc. |
Combination therapies and uses thereof
|
|
BR112020006669A2
(pt)
|
2017-10-11 |
2020-09-24 |
Aurigene Discovery Technologies Limited |
formas cristalinas de 1,2,4-oxadiazol 3-substituído
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US12275729B2
(en)
|
2017-11-01 |
2025-04-15 |
Merck Sharp & Dohme Llc |
Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
MY206121A
(en)
|
2017-11-03 |
2024-11-29 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
KR20200084333A
(ko)
|
2017-11-06 |
2020-07-10 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절을 위한 병행 요법
|
|
WO2019093383A1
(ja)
*
|
2017-11-07 |
2019-05-16 |
ジェイファーマ株式会社 |
抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法
|
|
EP3707272A4
(en)
|
2017-11-09 |
2021-11-24 |
The Trustees of The University of Pennsylvania |
EXTRACELLULAR VESICULAR PROTEINS AND THEIR USE FOR CANCER DIAGNOSIS, PREDICTION OF RESPONSE TO THERAPY AND TREATMENT
|
|
WO2019099294A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
AR113878A1
(es)
|
2017-11-14 |
2020-06-24 |
Merck Sharp & Dohme |
Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido)
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
JP6846574B2
(ja)
|
2017-11-29 |
2021-03-24 |
大鵬薬品工業株式会社 |
スルホンアミド化合物およびその使用
|
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019107389A1
(ja)
|
2017-12-01 |
2019-06-06 |
Ｓｂｉファーマ株式会社 |
免疫チェックポイント阻害剤による抗腫瘍効果を増強するための医薬組成物
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
MX2020006372A
(es)
|
2017-12-19 |
2020-09-03 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada.
|
|
CA3086219A1
(en)
|
2017-12-20 |
2019-06-27 |
Vlp Therapeutics, Llc |
Alphavirus replicon particle
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス， インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
|
WO2019134946A1
(en)
|
2018-01-04 |
2019-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US12286478B2
(en)
|
2018-01-23 |
2025-04-29 |
Nextcure, Inc. |
B7-H4 antibodies and methods of use thereof
|
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
CN112533613A
(zh)
|
2018-02-06 |
2021-03-19 |
通用医疗公司 |
作为肿瘤免疫应答的生物标志物的重复rna
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
CN112105642B
(zh)
|
2018-02-23 |
2023-01-31 |
祐和医药科技(北京)有限公司 |
抗pd-1抗体及其用途
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
WO2019177873A1
(en)
|
2018-03-13 |
2019-09-19 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
KR102495666B1
(ko)
|
2018-03-14 |
2023-02-06 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
|
MY203305A
(en)
|
2018-03-19 |
2024-06-23 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
CN120173101A
(zh)
|
2018-03-22 |
2025-06-20 |
表面肿瘤学有限责任公司 |
抗il-27抗体及其用途
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
AU2019251421B2
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US11746151B2
(en)
|
2018-04-13 |
2023-09-05 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
|
AU2019256383A1
(en)
|
2018-04-17 |
2020-11-26 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
|
EP3781689A1
(en)
|
2018-04-19 |
2021-02-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
US11542505B1
(en)
|
2018-04-20 |
2023-01-03 |
Merck Sharp & Dohme Llc |
Substituted RIG-I agonists: compositions and methods thereof
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
JP7557777B2
(ja)
|
2018-05-15 |
2024-09-30 |
デューク ユニバーシティ |
アッカーマンシア種の遺伝子操作のためのシステムおよび方法
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US12331068B2
(en)
|
2018-05-31 |
2025-06-17 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting CD73
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
CN118459594A
(zh)
|
2018-06-01 |
2024-08-09 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
|
WO2019245890A1
(en)
|
2018-06-20 |
2019-12-26 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
CN120714025A
(zh)
|
2018-06-20 |
2025-09-30 |
因赛特公司 |
抗pd-1抗体及其用途
|
|
BR112021000332A2
(pt)
|
2018-07-09 |
2021-04-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos químicos
|
|
KR20210042909A
(ko)
|
2018-07-09 |
2021-04-20 |
프레시전 인코포레이티드 |
융합 구조물 및 그의 이용 방법
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CN112703198B
(zh)
|
2018-07-11 |
2025-05-30 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
EP3833391A4
(en)
|
2018-08-08 |
2022-08-10 |
Orionis Biosciences, Inc. |
CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
|
|
AU2019328632A1
(en)
|
2018-08-27 |
2021-03-25 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
WO2020055702A1
(en)
|
2018-09-13 |
2020-03-19 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
WO2020067170A1
(ja)
|
2018-09-25 |
2020-04-02 |
国立研究開発法人国立循環器病研究センター |
抗腫瘍効果増強剤
|
|
EP3865141A4
(en)
|
2018-10-09 |
2022-06-08 |
Biocomo Incorporation |
ANTICANCER AGENT, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND KIT
|
|
BR112021007318A2
(pt)
|
2018-10-17 |
2021-08-31 |
Biolinerx Ltd. |
Tratamento de adenocarcinoma pancreático metastático
|
|
US12152019B2
(en)
|
2018-10-17 |
2024-11-26 |
Merck Sharp & Dohme Llc |
Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020086476A1
(en)
|
2018-10-22 |
2020-04-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
EP3873534A1
(en)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020092183A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
CN120983617A
(zh)
|
2018-11-06 |
2025-11-21 |
健玛保 |
抗体配制剂
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
CA3119311A1
(en)
|
2018-11-09 |
2020-05-14 |
Pierian Biosciences, LLC |
Methods and compositions for determining the composition of a tumor microenvironment
|
|
CN119735694A
(zh)
|
2018-11-13 |
2025-04-01 |
指南针制药有限责任公司 |
对抗检查点分子的多特异性结合构建体及其用途
|
|
HUE067601T2
(hu)
|
2018-11-14 |
2024-10-28 |
Regeneron Pharma |
PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
KR20210093946A
(ko)
|
2018-11-16 |
2021-07-28 |
아르퀼 인코포레이티드 |
암의 치료를 위한 제약 조합물
|
|
CA3116564A1
(en)
|
2018-11-19 |
2020-05-28 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-pd-1 antibodies and uses thereof
|
|
WO2020106558A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
EP3883964A1
(en)
|
2018-11-20 |
2021-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
WO2020106560A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
WO2020112581A1
(en)
|
2018-11-28 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
PE20211768A1
(es)
|
2018-11-30 |
2021-09-07 |
Merck Sharp & Dohme |
Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso
|
|
CN113613724B
(zh)
|
2018-11-30 |
2024-11-08 |
葛兰素史克知识产权开发有限公司 |
可用于hiv疗法的化合物
|
|
MX2021006430A
(es)
|
2018-12-03 |
2021-09-14 |
Agensys Inc |
Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas.
|
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
BR112021011224A2
(pt)
|
2018-12-11 |
2021-08-24 |
Theravance Biopharma R&D Ip, Llc |
Inibidores de alk5
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
SG11202105161YA
(en)
|
2018-12-13 |
2021-06-29 |
Surface Oncology Inc |
Anti-il-27 antibodies and uses thereof
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
WO2020131598A1
(en)
|
2018-12-18 |
2020-06-25 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
MX2021007271A
(es)
|
2018-12-21 |
2021-07-15 |
Onxeo |
Nuevas moleculas de acido nucleico conjugado y sus usos.
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
JP7737143B2
(ja)
|
2018-12-21 |
2025-09-10 |
エイム・イムノテック・インコーポレイテッド |
がん治療のための組成物および方法
|
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
|
CN109593135B
(zh)
*
|
2018-12-29 |
2021-01-15 |
百奥赛图江苏基因生物技术有限公司 |
抗人pd-l1单克隆抗体及其应用
|
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
|
KR20210143718A
(ko)
|
2019-01-17 |
2021-11-29 |
조지아 테크 리서치 코포레이션 |
산화된 콜레스테롤을 함유하는 약물 전달 시스템
|
|
WO2020149712A1
(ko)
|
2019-01-17 |
2020-07-23 |
오토텔릭바이오 주식회사 |
암 치료용 조성물
|
|
JP7574198B2
(ja)
|
2019-01-18 |
2024-10-28 |
ドラセン ファーマシューティカルズ インコーポレイテッド |
Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法
|
|
CN113366316B
(zh)
|
2019-01-30 |
2025-05-23 |
国家医疗保健研究所 |
用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物
|
|
MX2021009189A
(es)
|
2019-02-01 |
2021-11-12 |
Glaxosmithkline Ip Dev Ltd |
Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
|
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020165370A1
(en)
|
2019-02-13 |
2020-08-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924521A4
(en)
|
2019-02-15 |
2023-03-29 |
IncellDx, Inc. |
Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
|
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
|
MA55084A
(fr)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
|
|
WO2020180727A1
(en)
|
2019-03-06 |
2020-09-10 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
|
|
MA55516A
(fr)
|
2019-03-26 |
2022-02-09 |
Univ Michigan Regents |
Agents de dégradation, à petites molécules, de stat3
|
|
WO2020198662A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionfs Biosciences, Inc. |
Clec9a-based chimeric protein complexes
|
|
WO2020198654A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Therapeutic interferon alpha 1 proteins
|
|
AU2020252119B2
(en)
|
2019-03-29 |
2025-09-04 |
Centre National De La Recherche Scientifique - Cnrs |
Interleukin-2 variants with modified biological activity
|
|
EP3947403A1
(en)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
|
WO2020206169A1
(en)
|
2019-04-02 |
2020-10-08 |
Kupper Thomas S |
Methods for identifying progression of a primary melanoma
|
|
EP3946324B1
(en)
|
2019-04-04 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
WO2020214957A1
(en)
|
2019-04-19 |
2020-10-22 |
Tcrcure Biopharma Corp. |
Anti-pd-1 antibodies and uses thereof
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
JP2022531978A
(ja)
|
2019-05-15 |
2022-07-12 |
ネオティーエックス セラピューティクス リミテッド |
癌治療
|
|
WO2020232375A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Ｃｄｋ阻害剤を使用した組合せ療法
|
|
AU2020283299B2
(en)
|
2019-05-29 |
2024-08-01 |
Taiho Pharmaceutical Co., Ltd. |
Combination treatment of cancer using sulfonamide compound and immune regulator
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
AU2020291936A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
CN114222729A
(zh)
|
2019-06-12 |
2022-03-22 |
范德比尔特大学 |
氨基酸转运抑制剂及其用途
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
US20220233685A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
JP7329173B2
(ja)
|
2019-06-25 |
2023-08-18 |
東亞合成株式会社 |
抗腫瘍ペプチドおよびその利用
|
|
WO2020261097A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
|
US12485174B2
(en)
|
2019-06-27 |
2025-12-02 |
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation |
HDAC6-activated macrophages, compositions, and uses thereof
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
GB201910138D0
(en)
*
|
2019-07-15 |
2019-08-28 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
|
WO2021011713A1
(en)
|
2019-07-16 |
2021-01-21 |
The Regents Of The University Of Michigan |
Imidazopyrimidines as eed inhibitors and the use thereof
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US11155567B2
(en)
|
2019-08-02 |
2021-10-26 |
Mersana Therapeutics, Inc. |
Sting agonist compounds and methods of use
|
|
WO2021029368A1
(ja)
|
2019-08-09 |
2021-02-18 |
国立研究開発法人理化学研究所 |
人工アジュバントベクター細胞と免疫賦活化剤との併用
|
|
AU2020336381A1
(en)
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US12121565B2
(en)
|
2019-09-13 |
2024-10-22 |
Duke University |
Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
|
|
MX2022003005A
(es)
|
2019-09-16 |
2022-04-07 |
Surface Oncology Inc |
Composiciones y metodos de anticuerpos anti-cd39.
|
|
EP4031540A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
US20220411388A1
(en)
|
2019-09-17 |
2022-12-29 |
Bial - R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
AU2020349519A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021055756A1
(en)
|
2019-09-19 |
2021-03-25 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
JP2022549854A
(ja)
|
2019-09-25 |
2022-11-29 |
サーフィス オンコロジー インコーポレイテッド |
抗ｉｌ－２７抗体及びその使用
|
|
BR112022005787A2
(pt)
|
2019-09-27 |
2022-06-21 |
Glaxosmithkline Ip Dev Ltd |
Proteínas de ligação a antígeno
|
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
US12380963B2
(en)
|
2019-10-14 |
2025-08-05 |
The Medical College Of Wisconsin, Inc. |
Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
|
|
CA3157889A1
(en)
|
2019-10-17 |
2021-04-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
|
US20220401539A1
(en)
|
2019-10-22 |
2022-12-22 |
Institut Curie |
Immunotherapy Targeting Tumor Neoantigenic Peptides
|
|
WO2021081353A1
(en)
|
2019-10-23 |
2021-04-29 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
CN112724127B
(zh)
|
2019-10-28 |
2023-02-17 |
中国科学院上海药物研究所 |
五元杂环氧代羧酸类化合物及其医药用途
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
JP7691418B2
(ja)
|
2019-10-29 |
2025-06-11 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
癌を治療するためのＰＤ－１アンタゴニスト、ＶＥＧＦＲ／ＦＧＦＲ／ＲＥＴチロシンキナーゼ阻害剤、及びＣＢＰ／β－カテニン阻害剤の組合せ
|
|
WO2021091964A1
(en)
|
2019-11-04 |
2021-05-14 |
Duke University |
Treatment for primary and metastatic cancer
|
|
JP2023500054A
(ja)
|
2019-11-07 |
2023-01-04 |
オンクセルナ セラピューティクス，インコーポレイテッド |
腫瘍微小環境の分類
|
|
BR112022008020A2
(pt)
|
2019-11-13 |
2022-07-12 |
Taiho Pharmaceutical Co Ltd |
Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
EP3824954A1
(en)
|
2019-11-22 |
2021-05-26 |
Centre National de la Recherche Scientifique |
Device, apparatus and method for minibeam radiation therapy
|
|
JP2023502662A
(ja)
|
2019-11-22 |
2023-01-25 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
|
|
US20210154281A1
(en)
|
2019-11-26 |
2021-05-27 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
GB201917252D0
(en)
*
|
2019-11-27 |
2020-01-08 |
|
Pharmaceutic compositions
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
WO2021126725A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
JP7662644B2
(ja)
|
2019-12-18 |
2025-04-15 |
シーティーエックスティー・ピーティーワイ・リミテッド |
化合物
|
|
AU2020408198A1
(en)
|
2019-12-19 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
JP2023506958A
(ja)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
|
|
US20230140132A1
(en)
|
2020-01-07 |
2023-05-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
CA3167290A1
(en)
|
2020-01-10 |
2021-07-15 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
US20230086603A1
(en)
*
|
2020-01-21 |
2023-03-23 |
Bolt Biotherapeutics, Inc |
Anti-pd-l1 antibodies
|
|
CA3167689A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2021152005A1
(en)
|
2020-01-28 |
2021-08-05 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
EP4100059A1
(en)
|
2020-02-04 |
2022-12-14 |
Genmab A/S |
Antibodies for use in therapy
|
|
EP4100126A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
EP4110955A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
WO2021195481A1
(en)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
|
US11673879B2
(en)
|
2020-03-31 |
2023-06-13 |
Theravance Biopharma R&D Ip, Llc |
Substituted pyrimidines and methods of use
|
|
BR112022019919A2
(pt)
|
2020-04-02 |
2023-02-14 |
Mersana Therapeutics Inc |
Conjugado de anticorpo-fármaco compreendendo agonistas de sting
|
|
CN115698075A
(zh)
|
2020-04-14 |
2023-02-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
|
|
US20230149543A1
(en)
|
2020-04-14 |
2023-05-18 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
|
|
WO2021209356A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN115867658A
(zh)
|
2020-04-17 |
2023-03-28 |
Vlp治疗公司 |
冠状病毒疫苗
|
|
EP4139341A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
AU2021264216A1
(en)
|
2020-04-30 |
2022-11-10 |
Vlp Therapeutics, Inc. |
Cytokine immunotherapy
|
|
US20230183698A1
(en)
|
2020-05-01 |
2023-06-15 |
The University Of Tokyo |
Prophylactic or therapeutic agent for at least one type of cancer selected from group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma and liver cancer, prophylactic or therapeutic agent for said cancer which is used in combination drug in combination with said agent, combination drug comprising said agents, and method for screening for prophylactic or therapeutic agent for cancer
|
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
|
US12454525B2
(en)
|
2020-05-06 |
2025-10-28 |
Merck Sharp & Dohme Llc |
IL4I1 inhibitors and methods of use
|
|
JP7776145B2
(ja)
|
2020-05-13 |
2025-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
|
|
IL298136A
(en)
|
2020-05-13 |
2023-01-01 |
Bonum Therapeutics Inc |
Preparations of protein complexes and methods of using them
|
|
JP2023528293A
(ja)
|
2020-05-20 |
2023-07-04 |
アンスティテュ・クリー |
単一ドメイン抗体及びがん治療におけるその使用
|
|
IL298273A
(en)
|
2020-05-26 |
2023-01-01 |
Regeneron Pharma |
Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
PE20231082A1
(es)
|
2020-06-26 |
2023-07-17 |
Amgen Inc |
Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas
|
|
AU2021305234A1
(en)
|
2020-07-10 |
2023-02-09 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
US20230233690A1
(en)
|
2020-07-10 |
2023-07-27 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3168743A1
(en)
|
2020-08-26 |
2022-03-03 |
Matthew G. Fury |
Methods of treating cancer by administering a pd-1 inhibitor
|
|
JP2023540490A
(ja)
|
2020-09-02 |
2023-09-25 |
ファーマブシン インコーポレイテッド |
がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
|
|
WO2022051448A1
(en)
|
2020-09-03 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
|
CN111920948B
(zh)
*
|
2020-09-25 |
2021-02-02 |
安可瑞(山西)生物细胞有限公司 |
包含免疫细胞的药物组合物用于治疗癌症
|
|
WO2022072820A1
(en)
|
2020-10-02 |
2022-04-07 |
Dracen Pharmaceuticals, Inc. |
Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
|
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
|
EP4232453A1
(en)
|
2020-10-20 |
2023-08-30 |
Institut Curie |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
WO2022092085A1
(ja)
|
2020-10-28 |
2022-05-05 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20230416830A1
(en)
|
2020-11-16 |
2023-12-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
WO2022101484A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
EP4247352A1
(en)
|
2020-11-18 |
2023-09-27 |
Institut Curie |
Dimers of biguanidines and their therapeutic uses
|
|
CN117083080A
(zh)
|
2020-12-07 |
2023-11-17 |
健玛保 |
抗体和紫杉烷联合疗法
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
US20240317890A1
(en)
|
2021-01-14 |
2024-09-26 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
WO2022165403A1
(en)
|
2021-02-01 |
2022-08-04 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
BR112023017296A2
(pt)
|
2021-03-02 |
2023-11-14 |
Glaxosmithkline Ip Dev Ltd |
Piridinas substituídas como inibidores de dnmt1
|
|
US20240166647A1
(en)
|
2021-03-03 |
2024-05-23 |
The Regents Of The University Of Michigan |
Cereblon Ligands
|
|
US20240190874A1
(en)
|
2021-03-03 |
2024-06-13 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
AU2022242000A1
(en)
|
2021-03-23 |
2023-09-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
AU2022245322A1
(en)
|
2021-03-25 |
2023-10-05 |
Oncxerna Therapeutics, Inc. |
Targeted therapies in cancer
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
US20240166747A1
(en)
|
2021-03-31 |
2024-05-23 |
Glazosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
US12016860B2
(en)
|
2021-04-08 |
2024-06-25 |
Nurix Therapeutics, Inc. |
Combination therapies with Cbl-b inhibitor compounds
|
|
BR112023021111A2
(pt)
|
2021-04-13 |
2023-12-19 |
Nuvalent Inc |
Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
|
US20240269282A1
(en)
|
2021-05-10 |
2024-08-15 |
Institut Curie |
Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US20240239907A1
(en)
|
2021-05-25 |
2024-07-18 |
Edelweiss Immune Inc |
C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
TW202313117A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
EP4351595A1
(en)
|
2021-06-07 |
2024-04-17 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
EP4362984A1
(en)
|
2021-07-02 |
2024-05-08 |
Yale University |
Compositions and methods for treating cancers
|
|
AU2022314735A1
(en)
|
2021-07-19 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
|
US20250009877A1
(en)
|
2021-07-30 |
2025-01-09 |
Seagen Inc. |
Treatment for cancer
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
WO2023011879A1
(en)
|
2021-08-05 |
2023-02-09 |
Institut Curie |
Scanning dynamic device for minibeams production
|
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
CN117858897A
(zh)
|
2021-08-25 |
2024-04-09 |
东亚合成株式会社 |
抗pd-1信号肽抗体及其应用
|
|
WO2023034864A1
(en)
|
2021-08-31 |
2023-03-09 |
Yale University |
Compositions and methods for treating cancers
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
|
IL311771A
(en)
|
2021-10-06 |
2024-05-01 |
BioNTech SE |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
EP4412714A1
(en)
|
2021-10-06 |
2024-08-14 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
|
|
EP4427044A1
(en)
|
2021-11-03 |
2024-09-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
US20250019708A1
(en)
|
2021-11-19 |
2025-01-16 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
CN118660964A
(zh)
|
2021-12-16 |
2024-09-17 |
瓦莱里奥治疗公司 |
新型缀合核酸分子及其用途
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
US20250041261A1
(en)
|
2021-12-21 |
2025-02-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
AU2023212994A1
(en)
|
2022-01-28 |
2024-08-08 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
IL314851A
(en)
|
2022-02-17 |
2024-10-01 |
Regeneron Pharma |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
EP4493189A1
(en)
|
2022-03-14 |
2025-01-22 |
Laekna Limited |
Combination treatment for cancer
|
|
US20250302930A1
(en)
|
2022-03-24 |
2025-10-02 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
|
WO2023187024A1
(en)
|
2022-03-31 |
2023-10-05 |
Institut Curie |
Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
|
|
US20250241949A1
(en)
|
2022-04-07 |
2025-07-31 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
|
|
US20250222106A1
(en)
|
2022-04-07 |
2025-07-10 |
Institut Curie |
Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CA3257280A1
(en)
|
2022-05-25 |
2023-11-30 |
Msd International Gmbh |
COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
EP4568670A1
(en)
|
2022-08-10 |
2025-06-18 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
JPWO2024043319A1
(enExample)
|
2022-08-26 |
2024-02-29 |
|
|
|
EP4587040A1
(en)
|
2022-09-14 |
2025-07-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
EP4593868A1
(en)
|
2022-09-26 |
2025-08-06 |
Institut Curie |
Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
|
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
EP4622631A1
(en)
|
2022-11-23 |
2025-10-01 |
University of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
|
TW202430560A
(zh)
|
2023-01-06 |
2024-08-01 |
美商拉森醫療公司 |
抗ｉｌ－１８ｂｐ抗體
|
|
KR20250133728A
(ko)
|
2023-01-06 |
2025-09-08 |
라센 테라퓨틱스, 인코포레이티드 |
항-il-18bp 항체
|
|
JPWO2024150525A1
(enExample)
|
2023-01-12 |
2024-07-18 |
|
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
AU2024231397A1
(en)
|
2023-03-07 |
2025-09-25 |
Photocure Asa |
Therapy for bladder cancer
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
US20240336608A1
(en)
|
2023-03-29 |
2024-10-10 |
Merck Sharp & Dohme Llc |
Il4i1 inhibitors and methods of use
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
AU2024252845A1
(en)
|
2023-04-06 |
2025-10-16 |
Glaxosmithkline Intellectual Property (No.4) Limited |
Methods for treating and monitoring cancer
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024213782A1
(en)
|
2023-04-13 |
2024-10-17 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
TW202509069A
(zh)
|
2023-05-04 |
2025-03-01 |
美商諾瓦森塔股份有限公司 |
抗cd161抗體及其使用方法
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2025046272A1
(en)
|
2023-08-31 |
2025-03-06 |
Taiho Pharmaceutical Co., Ltd. |
Methods of treating cancer using futibatinib and pembrolizumab
|
|
WO2025049858A1
(en)
|
2023-09-01 |
2025-03-06 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025080538A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
TW202523359A
(zh)
|
2023-10-24 |
2025-06-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
|
|
WO2025096843A1
(en)
|
2023-11-03 |
2025-05-08 |
Amgen Inc. |
Bispecific molecules
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025151487A2
(en)
|
2024-01-08 |
2025-07-17 |
Regents Of The University Of Michigan |
Small-molecule inhibitors of adar1
|
|
WO2025158077A1
(en)
|
2024-01-26 |
2025-07-31 |
Institut Curie |
Lipid degraders to trigger ferroptosis in cancer
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025207705A1
(en)
|
2024-03-26 |
2025-10-02 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025202450A1
(en)
|
2024-03-28 |
2025-10-02 |
Institut Curie |
Myeloid cells modified by cytokine chimeric receptor and uses thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025210252A1
(en)
|
2024-04-05 |
2025-10-09 |
Institut Curie |
Modulators of fam118b protein for use in therapy
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025232879A1
(en)
|
2024-05-10 |
2025-11-13 |
Cytocares (Shanghai) Inc. |
Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|